Mythic Therapeutics Faces An Acid Test

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

Antibody-drug conjugates are big business, with the market leader, AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu (trastuzumab deruxtecan), forecast to make more than $14bn in 2030 according to Evaluate Pharma.

This has inspired many followers, many of which are working on optimizing either the chemotherapy payload or linker technology used...